Invalid Symbol

Stock Research for OPHT

OPHT
Current Price

$


Latest Update:

High
$
Low
$
Close
$
Volume
 
  

Featured Broker: TradeStation

Get the due diligence for another stock.

 

OPHT Stock Chart & Research Data

The OPHT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the OPHT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


OPHT Due diligence Resources & Stock Charts

The OPHT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View OPHT Detailed Price Forecast - CNN Money CNN View OPHT Detailed Summary - Google Finance
Yahoo View OPHT Detailed Summary - Yahoo! Finance Zacks View OPHT Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View OPHT Trends & Analysis - Trade-Ideas Barrons View OPHT Major Holders - Barrons
NASDAQ View OPHT Call Transcripts - NASDAQ Seeking View OPHT Breaking News & Analysis - Seeking Alpha
Spotlight View OPHT Annual Report - CompanySpotlight.com OTC Report View OPHT OTC Short Report - OTCShortReport.com
TradeKing View OPHT Fundamentals - TradeKing Charts View OPHT SEC Filings - Bar Chart
WSJ View Historical Prices for OPHT - The WSJ Morningstar View Performance/Total Return for OPHT - Morningstar
MarketWatch View the Analyst Estimates for OPHT - MarketWatch CNBC View the Earnings History for OPHT - CNBC
StockMarketWatch View the OPHT Earnings - StockMarketWatch MacroAxis View OPHT Buy or Sell Recommendations - MacroAxis
Bullish View the OPHT Bullish Patterns - American Bulls Short Pains View OPHT Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View OPHT Stock Mentions - StockTwits PennyStocks View OPHT Stock Mentions - PennyStockTweets
Twitter View OPHT Stock Mentions - Twitter Invest Hub View OPHT Investment Forum News - Investor Hub
Yahoo View OPHT Stock Mentions - Yahoo! Message Board Seeking Alpha View OPHT Stock Mentions - Seeking Alpha




Financial & Transaction Holdings

SECform4 View Insider Transactions for OPHT - SECform4.com Insider Cow View Insider Transactions for OPHT - Insider Cow
CNBC View OPHT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for OPHT - OTC Markets
Yahoo View Insider Transactions for OPHT - Yahoo! Finance NASDAQ View Institutional Holdings for OPHT - NASDAQ


Stock Charts

FinViz View OPHT Stock Insight & Charts - FinViz.com StockCharts View OPHT Investment Charts - StockCharts.com
BarChart View OPHT Stock Overview & Charts - BarChart Trading View View OPHT User Generated Charts - Trading View


Latest Financial News for OPHT

Market Trends Toward New Normal in Innospec, Southern Copper, Cornerstone OnDemand, Eagle, Northwest Natural Gas, and Ophthotech — Emerging Consolidated Expectations, Analyst Ratings
Posted on Friday February 09, 2018

NEW YORK, Feb. 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Innospec ...


Nektar’s Deals: Daiichi Sankyo, Ophthotech, Bristol-Myers Squibb
Posted on Wednesday January 24, 2018

A Look at Nektar Therapeutics' Revenue Drivers in 2018


Ophthotech Begins Phase II Zimura Study in Stargardt Disease
Posted on Wednesday January 17, 2018

Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.


Ophthotech Announces First Patient Enrolled in the Phase 2b Clinical Trial of Zimura®, Complement C5 Inhibitor, for the Treatment of Autosomal Recessive Stargardt Disease (STGD1)
Posted on Tuesday January 16, 2018

Ophthotech Corporation announced today that the first patient has been enrolled in the Phase 2b randomized, double-masked, sham-controlled clinical trial assessing the efficacy and safety of Zimura® , complement C5 inhibitor, in patients with autosomal recessive Stargardt disease .


Ophthotech: 3 Strikes And It's Out?
Seeking Alpha - Aug 21, 2017
Recently, Ophthotech (OPHT) announced results for is phase 3 trial treating patients with wet age-related macular degeneration (wet AMD).

$-0.58 EPS Expected for Ophthotech Corporation (OPHT)
BZ Weekly - 3 hours ago
Bnp Paribas Arbitrage Sa holds 0% in Ophthotech Corporation (NASDAQ:OPHT) or 60 shares. Quantitative Investment Management Limited Liability Company invested in 0.01% or 319,300 shares.
EPS for Ophthotech Corporation (OPHT) Expected At $-0.58 - Reurope

Ophthotech Corp: DE Shaw & Co Makes Purchase
BZ Weekly - Feb 16, 2018
Tower Research Cap Limited Liability (Trc) invested 0% in Ophthotech Corporation (NASDAQ:OPHT). Employees Retirement Association Of Colorado reported 5,054 shares stake.
Ophthotech Corp: DE Shaw & Co Opened Position - KL Daily

Delving into the Stochastic Momentum For Ophthotech Corp (OPHT)
Aurora Gazette - 14 hours ago
Investors are delving into the details on shares of Ophthotech Corp (OPHT). The share price has climbed the ladder moving past the Stochtastic Momentum Index of +40, indicating possible overbought territory.

Enter a stock symbol to view the stock details.